TLX — Telix Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- AU$4.19bn
- AU$4.08bn
- AU$502.55m
Annual income statement for Telix Pharmaceuticals, fiscal year end - December 31st, AUD millions except per share, conversion factor applied.
C2019 December 31st | 2020 December 31st | 2021 December 31st | C2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 3.48 | 5.21 | 7.6 | 160 | 503 |
| Cost of Revenue | |||||
| Gross Profit | 0.942 | 3.19 | 5.05 | 94.9 | 314 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 34.5 | 52 | 82.8 | 252 | 487 |
| Operating Profit | -31 | -46.8 | -75.2 | -91.9 | 15.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -31.1 | -47.9 | -80.5 | -98.6 | 3.09 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -27.9 | -44.9 | -80.5 | -104 | 5.21 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -27.9 | -44.9 | -80.5 | -104 | 5.21 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -27.9 | -44.9 | -80.5 | -104 | 5.21 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.119 | -0.174 | -0.285 | -0.335 | 0.018 |